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Abstract 36 
Aims Supervised exercise reduces liver fat and improves endothelial function, a surrogate of 37 
cardiovascular disease risk, in non-alcoholic fatty liver disease (NAFLD). We hypothesised 38 
that after a 16-week supervised exercise program, patients would maintain longer-term 39 
improvements in cardiorespiratory fitness, liver fat and endothelial function.  40 
Matherials and Methods. Ten NAFLD patients [5/5 males/females, age 51±13years, BMI 41 
31±3kg.m2 (mean±SD)] underwent a 16-week supervised moderate-intensity exercise 42 
intervention. Biochemical markers, cardiorespiratory fitness (VO2peak), subcutaneous, visceral 43 
and liver fat (measured by magnetic resonance imaging and spectroscopy respectively) and 44 
brachial artery flow-mediated dilation (FMD) were assessed at baseline, after 16 weeks 45 
supervised training and 12-months after ending supervision. 46 
Results Despite no significant change in body weight, there were significant improvements in 47 
VO2peak [6.5ml.kg
-1.min-1 (95% CI 2.8, 10.1); P=0.003], FMD [2.9% (1.5, 4.2); P=0.001], 48 
liver transaminases (P<0.05) and liver fat [-10.1% (-20.6, 0.5); P=0.048] immediately after 49 
the 16-weeks supervised training. Nevertheless, 12-months after ending supervision, VO2peak 50 
[0.9ml.kg-1.min-1 (-3.3 5.1); P=0.65], FMD [-0.07% (-2.3, 2.2); P=0.95], liver transaminases 51 
(P>0.05) and liver fat [1.4% (-13.0, 15.9); P=0.83] were not significantly different from 52 
baseline.  53 
Conclusions Twelve months following cessation of supervision, exercise-mediated 54 
improvements in liver fat and other cardiometabolic variables had reversed with 55 
cardiorespiratory fitness at baseline levels. Maintenance of high cardiorespiratory fitness and 56 
stability of body weight are critical public health considerations for the treatment of NAFLD. 57 
 58 
 59 
 60 
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Introduction 61 
Non-alcoholic fatty liver disease (NAFLD) increases liver-related morbidity and mortality1, 62 
yet cardiovascular disease (CVD) is the leading cause of its mortality2. We need effective 63 
sustainable interventions to reverse NAFLD and reduce cardiovascular risk. In the absence of 64 
approved pharmacological treatment, structured exercise and/or dietary modification are 65 
recommended first-line treatment in NAFLD3. The cardiometabolic benefits of supervised 66 
exercise, which include reduced liver fat, enhanced peripheral insulin sensitivity and 67 
microvascular and conduit-artery endothelial function 4, 5, do not require weight loss. Parallel 68 
improvements in liver fat and cardiac structure and function 6 emphasise the role of exercise 69 
as an intervention to reduce both hepatic and CVD risk.  70 
We hypothesised that after a 16-week supervised exercise program, patients would maintain 71 
the longer-term improvements in cardiorespiratory fitness, liver fat and endothelial function. 72 
To test this we re-examined a subset of previously-reported patients 4, 5 a year after ending 73 
exercise supervision.  74 
 75 
Methods  76 
At baseline, NAFLD was diagnosed by a hepatologist based on raised transaminases (after 77 
exclusion of secondary causes) with confirmation of elevated liver fat (≥5.5%) by magnetic 78 
resonance spectroscopy (1H MRS). All participants were physically inactive (<2 h/week low-79 
intensity physical activity) Caucasians, with no history of excessive alcohol intake (males 80 
<21, females <14 units/week); normotensive, normoglycaemic non-smokers with no 81 
contraindications to exercise; females were post-menopausal.  82 
Patients who completed a 16-week structured and supervised exercise intervention were 83 
offered the opportunity to repeat assessments 12-months later. From the original study cohort, 84 
10 patients who completed the exercise intervention 4, 5 (5 males, 5 females; 51±13y; BMI 85 
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31±3kg.m-2) underwent repeat assessments 12-months later. All participants remained with 86 
similar alcohol intake and as normotensive, normoglycaemic non-smokers. Liverpool Central 87 
Research Ethics Committee approved the study, and all participants gave written informed 88 
consent. 89 
Measurements were performed fasted at baseline, after 16-weeks supervised exercise training 90 
and 12-months after its end5. Anthropometric measurements were taken and blood samples 91 
collected for plasma glucose, lipid profiles and liver enzymes. 92 
Magnetic resonance scanning at 1.5T was as previously described5. Abdominal visceral 93 
(VAT) and subcutaneous adipose tissue (SAT) were calculated from whole-body axial T1-94 
weighted fast spin echo scans. Total abdominal adipose tissue (AT) = VAT + SAT. Liver fat 95 
was measured using 1H MRS and expressed as % CH2 lipid amplitude relative to water signal. 96 
High-resolution ultrasound (Terason, t3000, Aloka, UK) was used to image the brachial 97 
artery after 30min supine rest. Endothelial-dependent function was assessed as flow-mediated 98 
dilation (FMD): brachial artery diameter, flow and shear stress were measured before and 99 
after 5min forearm cuff inflation, and FMD is peak artery diameter following hyperaemia, 100 
expressed as % increase using an allometric model. Endothelium-independent function was 101 
assessed by imaging 1min before and 10min after sublingual (400 μg) glyceryl trinitrate 102 
(GTN)7.  103 
Cardiorespiratory fitness5 was assessed on a treadmill ergometer, initially 2.7 km.h-1 at 5° 104 
gradient, with step-wise increments every minute. VO2peak was calculated from expired gas 105 
(Oxycon Pro, Jaegar, Germany) as the highest consecutive 15s periods of oxygen uptake in 106 
the last minute before exhaustion. No self-reported or objective assessment of physical 107 
activity and/or exercise was made following the cessation the 16-week structured exercise 108 
intervention.  109 
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For the exercise training intervention, an exercise physiologist provided supervision and 110 
guidance. Based upon individual basal fitness, participants underwent 30min moderate 111 
intensity aerobic exercise 3 times/week at 30% heart rate reserve (HRR), progressing weekly 112 
based on HR responses in the initial 4-weeks. Intensity increased to 45% HRR for the 113 
following 4-weeks, until week 8, where HRR remained at 45% but each session increased to 114 
45min. From week 12, participants were exercising 5 times/week for 45min at 60% HRR. 115 
Upon completion of the supervised exercise patients had no contact from the research team 116 
for 12-months.  117 
A general linear model with repeated measures was employed to evaluate differences 118 
between baseline, immediate and 12-months post-training data. Analyses were performed 119 
using SPSS 21.0 (SPSS, Chicago, Illinois). All data in the text, figure and table, including 120 
changes, are presented as mean (95% confidence intervals), except age and BMI (presented 121 
as mean and standard deviation). Intra-observer coefficients of variation for measurements of 122 
liver fat and FMD were 6.0 
8 and 6.7 % 9, respectively. 123 
 124 
Results 125 
Body weight did not change significantly from baseline over the training period [change = -126 
1.9kg (-1.5, 5.2); P=0.29], or 12-months following its completion [-0.2kg, (-3.6, 3.1); 127 
P=0.90; Figure 1]. 128 
VO2peak increased [6.5ml.kg
-1.min-1 (95% CI 2.8, 10.1); P=0.003] and waist circumference 129 
decreased [-6cm (-9, -2); P=0.004] following training, but had returned to baseline 12-months 130 
later [0.9ml.kg-1.min-1 (-3.3, 5.1); P=0.67; Figure 1 & -1cm (-7, 5); P=0.60; Table 1 131 
respectively].  132 
 6 
Liver fat [-10.1% (-20.6, 0.5); P=0.048], ALT [-20u/L (-41, 1); P=0.05] and AST [-11u/L (-133 
21, -1); P=0.04] decreased following training but had returned to baseline 12-months later 134 
[1.4% (-13.0, 15.9); P=0.83]; Figure 1; 10u/L (-21, 41); P=0.48 & 2u/l (-11, 16); P=0.70; 135 
Table 1 respectively]. There were no significant changes in VAT, SAT or total AT (P>0.20; 136 
Table 1).  137 
FMD improved [2.9% (1.5, 4.2); P=0.001] following training, but had returned to baseline 12 138 
months later [-0.07% (-2.3, 2.2); P=0.95; Figure 1]. There were no significant differences in 139 
endothelium-independent (GTN-mediated) dilation (P=0.74; Table 1). 140 
Patients who lost the most weight during the 16-week intervention period had the smallest 141 
gain in liver fat between weeks 16 and 68 (P=0.03); 1kg reduction in body weight at 16-142 
weeks reduced the change in liver fat by ~4.5% in the following 52-week period. 143 
 144 
Conclusion 145 
Longitudinal data suggest that whilst vigorous physical activity can prevent liver fat 146 
accumulation, adherence to current national and international physical activity guidelines 147 
alone is not sufficient to prevent NAFLD 10. A recent study demonstrated that 8-weeks 148 
aerobic exercise can reduce liver fat, irrespective of exercise volume and intensity 11. 149 
Following 16-weeks of supervised exercise training in the present cohort, liver fat 150 
significantly decreased and FMD increased by 2.8%, extrapolated from meta-analysis data to 151 
confer a CVD risk reduction of ~17% 12. Nevertheless, this improvement had disappeared 12-152 
months after cessation of exercise supervision.  153 
To the authors’ knowledge, no study to date has undertaken longer-term follow-up of the 154 
exercise-induced improvements in liver and vascular health following cessation of 155 
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supervision. This study suggests that short-term exercise interventions have only short-term 156 
benefits.  157 
By contrast, improvements in liver transaminases, liver fat and insulin resistance observed 158 
after a 6-month hypocaloric diet with dietary counselling, were maintained for 17-36 months 159 
after ending counselling, despite modest weight regain 13; but this study did not examine the 160 
effects on CVD risk, the leading cause of mortality in NAFLD 2, 14. In our study, changes in 161 
liver fat and FMD were strongly associated with changes in cardiorespiratory fitness, 162 
suggesting that maintenance of exercise-induced improvements in cardiometabolic 163 
parameters depends upon sustained cardiorespiratory fitness. It therefore appears that 164 
exercise and hypocaloric diet interventions modulate liver fat content across different time 165 
courses and perhaps via distinct mechanisms. Indeed, as little as 7 consecutive days of 60min 166 
treadmill walking improves liver fat and increases insulin sensitivity in obese individuals 167 
with NAFLD 15. These data suggest that an increase in levels of physical activity with 168 
exercise training dynamically modulates liver fat, and that to achieve prolonged 169 
cardiometabolic benefits, higher levels of fitness must be maintained. Although the patients 170 
were counselled on the benefits of exercise and encouraged to maintain their exercise training 171 
without further guidance, physical fitness returned to pre-intervention level, suggesting that 172 
long-term supervision or alternative strategies of exercise provision are required.  173 
Limitations of this exploratory pilot study include a relatively small patient cohort, and a lack 174 
of intermediate post-intervention assessments and measures of insulin resistance. Follow up 175 
assessments were based on patient choice and thus there is the possibility of cohort bias.  176 
In summary, whilst 16-weeks of supervised exercise effectively improves liver fat and 177 
endothelial function in NAFLD, the cardiometabolic benefit of training is not sustained 1 178 
year after ending supervision. To overcome the NAFLD epidemic we need an effective 179 
mechanism to promote long-term maintenance of fitness.  180 
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203 
Figure 1 Changes in A) cardiorespiratory fitness (VO2peak), B) liver fat (%), C) flow 204 
mediated dilatation (FMD) (%) and D) body weight at baseline (‘Pre-ex’), following 16 205 
weeks of supervised exercise training (‘Post-ex’) and 12-months following cessation of 206 
exercise supervision (‘1 year’). Data are presented as mean (95% CI) and as individual 207 
patients’ values.  208 
 10 
Table 1 Characteristics of NAFLD patients at baseline (‘Pre-Ex’), immediately 209 
following 16-weeks of supervised exercise training (‘Post-ex’) and 12 months following 210 
(‘1 year’) the cessation of supervised exercise. 211 
 212 
 Pre-Ex Post-Ex 1 year P  
Anthropometrics     
Weight (kg) 84.4(75.6, 93.1) 82.1(72.7, 91.5) 83.8(70.6, 97.0) 0.40 
BMI (kg.m-2) 30(28, 32) 29(27, 31) 30(27, 33) 0.37 
Waist circumference (cm)  103(97, 108) 97(91, 104)† 101(97, 108)‡ 0.03 
Systolic BP (mmHg) 128(123, 134) 125(120, 130) 129(120,136) 0.23 
Diastolic BP (mmHg) 79(74, 85) 76(74, 81) 78(71,85) 0.59 
Fitness (L.min-1) 2.23 (1.61, 2.85) 2.73 (1.9,3.55)† 2.28 (1.63,2.93)‡ <0.01 
     
Liver Enzymes     
ALT (u.l-1)  57(33, 81) 37(25, 48)† 67(40, 94)‡ 0.05 
AST (u.l-1)  39(26, 51) 28(24, 31)† 41(31, 51)‡ 0.04 
GGT (u.l-1)  
 
85(18, 152) 60(18, 103) 68(38, 99) 0.26 
Glucose and Lipid Profile     
Glucose (mmol.l-1)  5.0(4.6,5.4) 4.9(4.5, 5.3) 5.2(4.7, 5.6) 0.40 
Cholesterol (mmol.l-1) 5.4(4.6, 6.1) 5.3(4.6, 5.9) 5.7(5.0, 6.5) 0.10 
Triglyceride (mmol.l-1)  2.0(1.6,2.4) 1.9(1.6,2.2) 1.9(1.4, 2.4) 0.85 
HDL (mmol.l-1) 1.4(1.2, 1.5) 1.4(1.3, 1.5) 1.5(1.3, 1.7) 0.16 
LDL (mmol.l-1) 3.1(2.6, 3.6) 3.0(2.4, 3.6) 3.3(2.6, 4.0) 0.12 
Chol:HDL ratio  
 
3.8(3.3, 4.4) 3.8(3.1, 4.5) 3.9(3.2, 4.6) 0.89 
Adipose tissue deposition     
VAT (l) 5.5(3.9, 7.1) 5.5(4.1, 6.8) 5.0(3.9, 6.0) 0.20 
SAT (l) 8.2(6.0, 10.3) 7.7(5.6, 9.8) 7.9(5.0, 10.8) 0.27 
Total abdominal AT (l) 
 
13.7(11.3, 16.0) 13.1(11.2, 15.1) 12.8(9.1, 15.5) 0.23 
Brachial Artery Function      
GTN-Mediated Dilation (%) 13.5(9.1, 17.8) 14.6(10.1, 19.0) 14.1(10.5, 18.7) 0.74 
 213 
Data are presented as mean (95% CI). † Significantly different from baseline (P<0.05). 214 
‡ Significantly different from immediately following 16 weeks of supervised exercise training 215 
(P<0.05). 216 
BMI Body mass index, BP blood pressure, ALT Alanine aminotransferase, AST Aspartate 217 
aminotransferase, GGT Gamma-glutamyltransferase, HDL High density lipoprotein, LDL 218 
Low density lipoprotein, VAT Visceral adipose tissue SAT Subcutaneous adipose tissue AT 219 
Adipose tissue GTN Glyceryl trinitrate 220 
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